A Twenty-years' Experience in Pituitary Disease.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients underwent surgery for pituitary tumors;
pathology diagnosis of pituitary tumors;
patients older then 18 years at diagnosis of pituitary tumors;
2 years follow-up;
Disqualifiers
age lower then 18 years
follow-up shorter than 2 years
Trial population
Patients older then 18 years with diagnosis of pituitary tumors (pituitary adenoma, pituitary neuroendocrine tumors, meningiomas, craniopharingiomas, germinoma, metastasis)
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Frequency of disease recurrence
Other interventionTo collect data of pituitary disease recurrence
Treatment groups
1,600 Participants
are divided into 1 treatment groupGroup A: Patients with pituitary tumors1 intervention
Trial outcomes
Primary outcomes
1
Tumor recurrence
Frequency of tumor recurrence at 24 months of follow-up
Time frame
From enrollement to last observation at 24 months of follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov